Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Offidani, Massimo
Corvatta, Laura
Maracci, Laura
Liberati, Anna Marina
Ballanti, Stelvio
Attolico, Immacolata
Caraffa, Patrizia
Alesiani, Francesco
di Toritto, Tommaso Caravita
Gentili, Silvia
Tosi, Patrizia
Brunori, Marino
Derudas, Daniele
Ledda, Antonio
Gozzetti, Alessandro
Cellini, Claudia
Malerba, Lara
Mele, Anna
Andriani, Alessandro
Galimberti, Sara
Mondello, Patrizia
Pulini, Stefano
Coppetelli, Ugo
Fraticelli, Paolo
Olivieri, Attilio
Leoni, Pietro
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1974.1974
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1974
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
    Offidani, Massimo
    Maracci, Laura
    Corvatta, Laura
    Marina, Liberati Anna
    Ballanti, Stelvio
    Attolico, Imma
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Felici, Stefano
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Rizzi, Rita
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [2] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [3] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [4] BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STUDY
    Offidani, M.
    Corvatta, L.
    Caraffa, P.
    Liberati, A. M.
    Alesiani, F.
    Brunori, M.
    di Toritto, T. Caravita
    Gentili, S.
    Attolico, I.
    Mele, A.
    Pulini, S.
    Ballanti, S.
    Galimberti, S.
    Gozzetti, A.
    Coppetelli, U.
    Ledda, A.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 353 - 353
  • [5] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
  • [6] Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Akos
    Bruns, Ingmar
    Neumann, Frank
    Fenk, Barbara
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2345 - 2351
  • [7] BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Nappi, D.
    Basile, S.
    Marano, L.
    Peluso, I
    Simeone, L.
    Vitagliano, O.
    Romano, A.
    Palmieri, S.
    Rocco, S.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2018, 103 : 38 - 38
  • [8] Bendamustine-Bortezomib-Dexamethasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
    Cerchione, Claudio
    Catalano, Lucio
    Pareto, Anna Emanuele
    Basile, Santina
    Marano, Luana
    Peluso, Ilaria
    Simeone, Luigia
    Vitagliano, Orsola
    Palmieri, Salvatore
    Rocco, Stefano
    Ferrara, Felicetto
    Pane, Fabrizio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E60 - E61
  • [9] BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Nappi, D.
    Di Perna, M.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2017, 102 : 138 - 139
  • [10] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345